Latest Blogs

May 19, 2022
Dr. Khalid El Bairi advises early-career researchers in low- and middle-income countries to focus first on learning universal methodology, then on targeted training for specific projects.
May 17, 2022
"If we, as knowledgeable people, start informing women whom we come across about cervical cancer screening, we add a drop to the ocean of wellness," said Dr. Pesona Grace Lucksom.
May 12, 2022
Since ASCO22 will be offered as a hybrid meeting, with both an in-person and a virtual experience, we get the best of both worlds.
May 12, 2022
Ellen Zhang shares an original poem inspired by the parent-child interactions she witnessed while working with pediatric patients with cancer.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a professor emeritus at the University of Colorado Cancer Center. He previously served as chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Disclosure.

Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
Nov 04, 2015
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.
Aug 05, 2015
Looking back on the 1976 Bonadonna study using CMF chemotherapy in women with breast cancer and positive axillary nodes, I consider what went wrong in the search for similarly effective treatment of prostate cancer.

Pages